|Bid||165.00 x 1000|
|Ask||177.16 x 800|
|Day's Range||174.82 - 177.70|
|52 Week Range||95.58 - 189.85|
|Beta (5Y Monthly)||1.20|
|PE Ratio (TTM)||35.54|
|Earnings Date||Jul 29, 2020 - Aug 03, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||184.40|
Zacks.com featured highlights include: Lowes Companies, Charles River Laboratories International, Agilent Technologies and East West
Charles River Laboratories International, Inc. (CRL) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2020. […]
HemaCare, a Charles River company, announced that it has expanded its portfolio with the launch of the GMPrime cryopreserved leukopak.
Horseshoe crabs' icy-blue blood will remain the drug industry's standard for safety tests after a powerful U.S. group ditched a plan to give equal status to a synthetic substitute pushed by Swiss biotech Lonza and animal welfare groups. The crabs' copper-rich blood clots in the presence of bacterial endotoxins and has long been used in tests to detect contamination in shots and infusions. More recently, man-made versions called recombinant Factor C (rFC) from Basel-based Lonza and others have emerged.
Toshiba Corporation (TOKYO: 6502, hereinafter "Toshiba") and a team led by Professor Yozo Nakazawa at the Department of Pediatrics, Shinshu University, (hereinafter "Shinshu University"), have together developed a "tumor-tropic liposome technology" for gene therapy*1. The technology uses unique, nano-sized biodegradable liposomes developed by Toshiba to accurately and efficiently deliver therapeutic genes to targeted cancer cells, and achieves safer gene delivery than viruses used as carriers.
Charles River Laboratories International (NYSE:CRL) shares have had a really impressive month, gaining 30%, after some...
Charles River Laboratories International, Inc. (NYSE:CRL), which is in the life sciences business, and is based in...
Charles River (CRL) delivered earnings and revenue surprises of 24.32% and 2.07%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Horizon Kinetics LLC, a New York-based investment advisory firm founded in 1994, released its Q1 2020 Commentary – a copy of which is available for download here. It has over 70 employees and is led by Murray Stahl. Its investment strategy is long-term and contrarian oriented, and the fund usually holds a concentrated portfolio with original […]
Medpace is building a base and near a possible buy range ahead of its earnings report expected around Apr. 28.
Those holding Charles River Laboratories International (NYSE:CRL) shares must be pleased that the share price has...
Charles River today announced that it has entered into a partnership with Deciphex, a leader in preclinical digital pathology software-as-a-service.
To the annoyance of some shareholders, Charles River Laboratories International (NYSE:CRL) shares are down a...
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
Charles River Laboratories appoints Nancy C. Andrews, M.D., Ph.D., Dean Emerita of Duke University’s School of Medicine, to its Board of Directors